Sinclair Pharma (SPH)

 

SPH Share PerformanceMore

52 week high36.350 17/01/17
52 week low25.250 16/10/17
52 week change -0.375 (-1.29%)
4 week volume4,685,626 23/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

New CE mark granted for Silhouette Soft

RNS Number: 1138U Sinclair Pharma PLC 19 October 2017 Sinclair Pharma plc New CE mark granted for Silhouette Soft London, 19 October 2017 Sinclair Pharma plc (SPH.L), ("Sinclair") the international aesthetics company, is pleased to announce that Silhouette Soft has been re-issued a European CE mark, effective immediately. As previously disclosed by Sinclair,...

Hardman Research: Demand growing in target markets

RNS Number: 3141S Sinclair Pharma PLC 02 October 2017 Hardman Research: Demand growing in target markets Demand growing in target markets - In 2016 Sinclair was transformed into a streamlined, pure-play aesthetics company with a concentrated, competitive portfolio of differentiated injectable products. Effective, longer-lasting, natural looking, minimally...

Interim Results

RNS Number: 0939R Sinclair Pharma PLC 19 September 2017 Sinclair Pharma plc Interim Results Strong underlying growth from key products, on track to meet full year guidance for EBITDA profit in 2017 Sinclair Pharma plc (SPH.L), ("Sinclair", or the "Group", or the "Company") the international aesthetics company, today announces its unaudited interim resu...

Holding(s) in Company

RNS Number: 8190K Sinclair Pharma PLC 12 July 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: SINCLAIR PHARM...

Hardman Research: Promising start in the US

RNS Number: 7651K Sinclair Pharma PLC 12 July 2017 Hardman Research: Promising start in the US Promising start in the US - In 2016 Sinclair was transformed into a streamlined, pure-play aesthetics company with a concentrated, highly competitive, portfolio of differentiated injectable products. Effective, longer-lasting, natural looking, minimally invasive treatm...

Sinclair Pharma lifts sales in 6 months to 30 June

Sinclair Pharma said its unaudited sales for the six months to 30 June were 20m, compared with sales of 17.2m for the sam...

Sinclair Pharma lifts sales in 6 months to 30 June

Trading Update for the 6 months to 30 June 2017

RNS Number: 6038K Sinclair Pharma PLC 11 July 2017 Trading Update for the 6 months to 30 June 2017 16% growth in revenues to 20 million FDA approves Silhouette label change accelerating growth potential On track for another year of strong growth London, 11 July 2017 Sinclair Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group"), the international aesthetics co...

Fundamental DataMore

EPS-5.9
Dividend yield0 %

Latest discussion posts More

  • CE registration

    RNS: 19/10/2017: New CE mark granted for Silhouette Soft?. Probably what has prompted the move up as people realise that the product has a globally recognised status as an EU ...
    23-Oct-2017
    PharmaD
  • Re: Interims

    Pretty much what the trading update said in July. It didn't impress the markets then as judged by the drift downwards.
    19-Sep-2017
    Red Ninja
  • Interims

    Revenue up 16%, strong 2nd half growth forecast and prediction of EDITDA profit for full year 2017. Slight worry that they have pretty much burnt through their cash pile ...
    19-Sep-2017
    charlus

Users' HoldingsMore

Users who hold Sinclair Pharma also hold..
LLOYDS GRP.43%
VODAFONE GRP.25%
BP25%
GLAXOSMITHKLINE25%
BARCLAYS22%

Codes & Symbols

ISINGB0033856740
SymbolsSPH, LSE:SPH, SPH.L, SPH:LN, LON:SPH, XLON:SPH

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account